CG Oncology (CGON) Competitors $33.47 +1.13 (+3.49%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CGON vs. ASND, LEGN, ELAN, BPMC, LNTH, NUVL, VKTX, CYTK, TGTX, and CRNXShould you be buying CG Oncology stock or one of its competitors? The main competitors of CG Oncology include Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), Lantheus (LNTH), Nuvalent (NUVL), Viking Therapeutics (VKTX), Cytokinetics (CYTK), TG Therapeutics (TGTX), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry. CG Oncology vs. Ascendis Pharma A/S Legend Biotech Elanco Animal Health Blueprint Medicines Lantheus Nuvalent Viking Therapeutics Cytokinetics TG Therapeutics Crinetics Pharmaceuticals CG Oncology (NASDAQ:CGON) and Ascendis Pharma A/S (NASDAQ:ASND) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability, community ranking and media sentiment. Does the MarketBeat Community prefer CGON or ASND? Ascendis Pharma A/S received 422 more outperform votes than CG Oncology when rated by MarketBeat users. However, 89.47% of users gave CG Oncology an outperform vote while only 66.52% of users gave Ascendis Pharma A/S an outperform vote. CompanyUnderperformOutperformCG OncologyOutperform Votes1789.47% Underperform Votes210.53%Ascendis Pharma A/SOutperform Votes43966.52% Underperform Votes22133.48% Which has stronger valuation and earnings, CGON or ASND? CG Oncology has higher earnings, but lower revenue than Ascendis Pharma A/S. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCG Oncology$200K11,317.88-$48.61MN/AN/AAscendis Pharma A/S$327.43M24.04-$521.07M-$8.08-16.07 Do insiders & institutionals believe in CGON or ASND? 26.6% of CG Oncology shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is CGON or ASND more profitable? Ascendis Pharma A/S has a net margin of -130.33% compared to CG Oncology's net margin of -10,642.98%. Ascendis Pharma A/S's return on equity of 0.00% beat CG Oncology's return on equity.Company Net Margins Return on Equity Return on Assets CG Oncology-10,642.98% -18.97% -15.36% Ascendis Pharma A/S -130.33%N/A -48.77% Does the media favor CGON or ASND? In the previous week, Ascendis Pharma A/S had 3 more articles in the media than CG Oncology. MarketBeat recorded 13 mentions for Ascendis Pharma A/S and 10 mentions for CG Oncology. CG Oncology's average media sentiment score of 1.09 beat Ascendis Pharma A/S's score of 0.32 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate CGON or ASND? CG Oncology presently has a consensus target price of $63.88, indicating a potential upside of 90.84%. Ascendis Pharma A/S has a consensus target price of $191.77, indicating a potential upside of 47.73%. Given CG Oncology's stronger consensus rating and higher probable upside, equities analysts clearly believe CG Oncology is more favorable than Ascendis Pharma A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CG Oncology 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Ascendis Pharma A/S 0 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.92 SummaryCG Oncology beats Ascendis Pharma A/S on 9 of the 16 factors compared between the two stocks. Ad Genesis Gold GroupTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov Get CG Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CGON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGON vs. The Competition Export to ExcelMetricCG OncologyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.26B$3.04B$5.38B$8.84BDividend YieldN/A1.91%5.13%4.09%P/E RatioN/A44.06102.4617.58Price / Sales11,317.88392.921,234.85158.43Price / CashN/A169.3840.4736.33Price / Book4.224.597.096.50Net Income-$48.61M-$41.63M$119.65M$226.22M7 Day Performance1.75%2.61%2.06%3.76%1 Month Performance-6.01%-2.47%-2.46%4.63%1 Year PerformanceN/A28.24%33.95%29.20% CG Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGONCG Oncology3.1834 of 5 stars$33.47+3.5%$63.88+90.8%N/A$2.26B$200,000.000.0061Positive NewsASNDAscendis Pharma A/S2.9978 of 5 stars$123.02-1.1%$191.77+55.9%+39.6%$7.54B$327.43M-15.22640Analyst UpgradeLEGNLegend Biotech1.4505 of 5 stars$39.75-1.0%$81.46+104.9%-31.9%$7.25B$285.14M-41.841,800ELANElanco Animal Health3.8657 of 5 stars$13.41-0.2%$17.14+27.9%+11.9%$6.63B$4.42B33.519,300BPMCBlueprint Medicines2.7235 of 5 stars$96.66+2.0%$122.11+26.3%+40.5%$6.14B$249.38M-45.81640Analyst RevisionLNTHLantheus4.6275 of 5 stars$87.32+1.0%$122.50+40.3%+32.5%$6.01B$1.50B14.53834Analyst DowngradePositive NewsNUVLNuvalent1.9519 of 5 stars$92.73+1.7%$112.60+21.4%+51.9%$6.01BN/A-26.7240VKTXViking Therapeutics4.7892 of 5 stars$51.75+0.4%$109.80+112.2%+354.9%$5.77BN/A-55.6420Analyst ForecastGap UpCYTKCytokinetics4.042 of 5 stars$47.67-4.4%$83.93+76.1%+53.9%$5.63B$7.53M-8.86250Analyst ForecastInsider TradeOptions VolumeTGTXTG Therapeutics3.6266 of 5 stars$34.74+11.5%$37.67+8.4%+176.8%$5.41B$233.66M-347.37290Positive NewsCRNXCrinetics Pharmaceuticals3.5808 of 5 stars$57.10+1.8%$70.18+22.9%+82.4%$5.30B$4.01M-15.31210 Related Companies and Tools Related Companies Ascendis Pharma A/S Competitors Legend Biotech Competitors Elanco Animal Health Competitors Blueprint Medicines Competitors Lantheus Competitors Nuvalent Competitors Viking Therapeutics Competitors Cytokinetics Competitors TG Therapeutics Competitors Crinetics Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CGON) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CG Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CG Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
